Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

v3.24.2.u1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Total
Ordinary shares
Reserves
Subscription Receivable
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Total Stockholders' Equity (Virax)
Non Controlling Interest
Number of shares, beginning balance at Mar. 31, 2021   923,103            
Equity, beginning balance at Mar. 31, 2021 $ (831,814) $ 924 $ 4,033,794 $ (54,497) $ (4,628,139) $ (2,764) $ (650,682) $ (181,132)
Shares issued for cash, shares   23,890            
Shares issued for cash 519,613 $ 24 519,589       519,613  
Shares issued for services, shares   34,635            
Shares issued for services 290,364 $ 35 290,329       290,364  
Shares issued for settlement of related party payable, shares   17,253            
Shares issued for settlement of related party payable 452,861 $ 17 452,844       452,861  
Shares issued for conversion of convertible debt. shares   3,774            
Shares issued for conversion of convertible debt 99,999 $ 3 99,996       99,999  
Surrender of ViraxClear Shares, shares   (5,000)            
Surrender of ViraxClear Shares   $ (5) (54,492) $ 54,497        
Imputed interest 21,128   21,128       21,128  
Foreign currency adjustment 1,010         965 965 45
Net Loss (1,749,870)       (1,708,827)   (1,708,827) (41,043)
Number of shares, ending balance at Mar. 31, 2022   997,655            
Equity, ending balance at Mar. 31, 2022 (1,196,709) $ 998 5,363,188   (6,336,966) (1,799) (974,579) (222,130)
Shares issued for cash, shares   425,750            
Shares issued for cash 13,654,215 $ 426 13,653,789       13,654,215  
Shares issued for services, shares   755            
Shares issued for services 20,000 $ 1 19,999       20,000  
Shares issued for settlement of related party payable, shares   5,430            
Shares issued for settlement of related party payable 39,864 $ 6 39,858       39,864  
Contributed capital - settlement of related party debt 109,570   109,570       109,570  
Cashless warrant exercise, shares   8,619            
Cashless warrant exercise 9 $ 9         9  
Pre-funded warrant exercise, shares   116,500            
Pre-funded warrant exercise 117 $ 117         117  
Stock-based compensation 1,734,601   1,734,601       1,734,601  
Foreign currency adjustment 111         111 111  
Net Loss $ (5,457,763)       (5,457,494)   (5,457,494) (269)
Number of shares, ending balance at Mar. 31, 2023 1,554,709 1,554,709            
Equity, ending balance at Mar. 31, 2023 $ 8,904,015 $ 1,557 20,921,005   (11,794,460) (1,688) 9,126,414 (222,399)
Pre-funded warrant exercise, shares   234,331            
Pre-funded warrant exercise 234 $ 234         234  
Warrant exercise, shares   734,073            
Warrant exercise 1,872,506 $ 734 1,871,772       1,872,506  
Shares issued for settlement of debt, shares   22,500            
Shares issued for settlement of debt 85,500 $ 21 85,479       85,500  
Shares issued for rounding on Share Consolidation, shares   28,290            
Shares issued for rounding on Share Consolidation 28 $ 28         28  
Stock-based compensation 1,011,973   1,011,973       1,011,973  
Foreign currency adjustment 3,639         3,639 3,639  
Net Loss $ (6,739,120)       (6,733,537)   (6,733,537) (5,583)
Number of shares, ending balance at Mar. 31, 2024 2,573,903 2,573,903            
Equity, ending balance at Mar. 31, 2024 $ 5,138,775 $ 2,574 $ 23,890,229   $ (18,527,997) $ 1,951 $ 5,366,757 $ (227,982)